Literature DB >> 7560255

Glyburide protein binding and the effect of albumin glycation in children, young adults, and older adults with diabetes.

K M Olsen1, G L Kearns, S F Kemp.   

Abstract

Because glyburide is a weak acid that is more than 98% bound to albumin, the authors evaluated the binding in vitro and the influence of albumin glycation in children, young adults, and older adults with diabetes mellitus. Glyburide binding to non-glycated albumin was greater than 98%, and remained constant over a total concentration range of 50 to 1000 ng/mL. Increasing the albumin concentration from 0.5 to 5.0 g/dL was logarithmically related to the free fraction of glyburide. After the in vitro glycation of albumin (range, 5.7-15.6%), mean (+/- SD) glyburide binding was 99.05 +/- 0.082%, a value in agreement with that obtained from control serum. Serum samples from 57 subjects with type I and 16 patients with type II diabetes were incubated with 300 ng/mL of unlabeled glyburide and 200 ng/mL of 14C-glyburide. The extent of albumin glycation varied from 5 to 22% for the type I subjects and 5 to 14% for the type II subjects. The free fraction from these groups ranged from 1.07 to 1.75% and 0.66 to 0.88% for the type I and type II subjects, respectively. Although these values did not differ significantly from those of the control samples, the glyburide free fraction in patients with type I diabetes (1.39 +/- 0.85%) was significantly greater than that found for the 16 elderly patients with type II diabetes (0.78 +/- 0.05%). A significant linear relationship was not found between glyburide free fraction and the degree of albumin glycation for either group. Glyburide protein binding did not appear to be influenced by the extent of albumin glycation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7560255     DOI: 10.1002/j.1552-4604.1995.tb04115.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

1.  Chromatographic studies of changes in binding of sulfonylurea drugs to human serum albumin due to glycation and fatty acids.

Authors:  Sara B G Basiaga; David S Hage
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-10-23       Impact factor: 3.205

Review 2.  Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor.

Authors:  Damayanthi Devineni; David Polidori
Journal:  Clin Pharmacokinet       Date:  2015-10       Impact factor: 6.447

3.  Advances in molecular imaging of pancreatic beta cells.

Authors:  Mai Lin; Angelo Lubag; Michael J McGuire; Serguei Y Seliounine; Edward N Tsyganov; Peter P Antich; A Dean Sherry; Kathlynn C Brown; Xiankai Sun
Journal:  Front Biosci       Date:  2008-05-01

4.  The Sur1-Trpm4 channel regulates NOS2 transcription in TLR4-activated microglia.

Authors:  David B Kurland; Volodymyr Gerzanich; Jason K Karimy; Seung Kyoon Woo; Rudi Vennekens; Marc Freichel; Bernd Nilius; Joseph Bryan; J Marc Simard
Journal:  J Neuroinflammation       Date:  2016-06-01       Impact factor: 8.322

5.  Salutary effects of glibenclamide during the chronic phase of murine experimental autoimmune encephalomyelitis.

Authors:  Volodymyr Gerzanich; Tapas K Makar; Poornachander Reddy Guda; Min Seong Kwon; Jesse A Stokum; Seung Kyoon Woo; Svetlana Ivanova; Alexander Ivanov; Rupal I Mehta; Alexandra Brooke Morris; Joseph Bryan; Christopher T Bever; J Marc Simard
Journal:  J Neuroinflammation       Date:  2017-09-02       Impact factor: 8.322

6.  Binding of sulphonylureas to plasma proteins - A KATP channel perspective.

Authors:  Peter Proks; Holger Kramer; Elizabeth Haythorne; Frances M Ashcroft
Journal:  PLoS One       Date:  2018-05-17       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.